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Abstract
Background: The aim of the study was to determine the effect of postmenopausal hormone
therapy on women's symptom reporting and quality of life in a randomized trial.
Methods: 1823 women participated in the Estonian Postmenopausal Hormone Therapy (EPHT)
Trial between 1999 and 2004. Women were randomized to open-label continuous combined
hormone therapy or no treatment, or to blind hormone therapy or placebo. The average follow-
up period was 3.6 years. Prevalence of symptoms and quality of life according to EQ-5D were
assessed by annually mailed questionnaires.
Results: In the hormone therapy arms, less women reported hot flushes (OR 0.20; 95% CI:
0.14–0.28), sweating (OR 0.56; 95% CI: 0.44–0.72), and sleeping problems (OR 0.66; 95% CI:
0.52–0.84), but more women reported episodes of vaginal bleeding (OR 19.65; 95% CI:
12.15–31.79). There was no difference between the trial arms in the prevalence of other symptoms
over time. Quality of life did not depend on hormone therapy use.
Conclusion: Postmenopausal hormone therapy decreased vasomotor symptoms and sleeping
problems, but increased episodes of vaginal bleeding, and had no effect on quality of life.
Trial registration number: ISRCTN35338757
Background
The effect of menopausal transition on women's lives is
complex and includes changes in physical health, psycho-
somatic domains, and personal life [1]. Health-related
quality of life may be severely compromised in women
with vasomotor symptoms [2]. Up to 40% of women in
Sweden experience vasomotor symptoms until the age of
64 years [3]. Postmenopausal hormone therapy has for a
long time been the recommended first choice to alleviate
hot flushes and night sweats [4-7]. Hormone therapy may
have side effects such as vaginal bleeding, breast tender-
ness, migraine headaches, mood alterations, and abdom-
inal bloating that may affect quality of life [8]. Besides
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related to postmenopausal status [9,10].
Population-based studies indicate that hormone therapy
improves vasomotor symptoms and sexual problems
[11], but not quality of life [12]. In the Heart and Estro-
gen/Progestin Replacement Study (HERS), women with
hot flushes had improvements in emotional measures of
quality of life [13]. In the Women's Health Initiative
(WHI) Trial, combined hormone therapy relieved some
menopausal symptoms, but contributed to side effects
[14], and no clinically meaningful effect on health-related
quality of life was found [15,16].
The Estonian Postmenopausal Hormone Therapy (EPHT)
Trial was a long-term preventive trial of hormone therapy
among healthy postmenopausal women. The EPHT Trial
consisted of two sub-trials: one blind and one non-blind.
Women were randomly allocated to combined continu-
ous hormone therapy or non-treatment, or to blind hor-
mone therapy or placebo. Their baseline health indicators
showed better health than those of the participants in the
WHI or HERS [17]. At baseline, women in the EPHT Trial
were aged on average 58 and were 8 years postmenopau-
sal compared to an average age of 63 years (13 years post-
menopausal) in the WHI Trial [14] and 67 years (18 years
postmenopausal) in the HERS Trial [13,18].
Besides studying the effect of postmenopausal hormone
therapy on the risk of cancer, cardiovascular diseases and
bone fractures [17] and the related use of health services
[19], the other major aims of the EPHT Trial were to ana-
lyze the effect of hormone therapy on symptom reporting
and health-related quality of life.
Methods
Participants
Postmenopausal women aged 50 to 64 and living in
Tallinn (the capital of Estonia), Tartu, and in two counties
surrounding these towns were asked to participate in a
postmenopausal hormone therapy trial. Potentially eligi-
ble women were randomized into four trial arms: 1) blind
hormone therapy arm, 2) blind placebo arm, 3) non-
blind hormone therapy arm, 4) non-treatment arm. Ran-
domization occurred before mailing the invitation to the
recruitment visit in order to study the impact of blinding
on recruitment. Randomized women were mailed an invi-
tation to the recruitment visit, indicating whether they
had been randomized to the blind or the non-blind sub-
trial (Figure 1). The non-blind sub-trial was designed to
Flow chart of the EPHT Trialigure 1
Flow chart of the EPHT Trial.
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utilization.
More women came to the recruitment visit in the non-
blind sub-trial, and more women signed the informed
consent during the recruitment visit in the non-blind sub-
trial. This resulted in 503 women recruited in the non-
blind hormone therapy arm, 524 in the non-treatment
arm, 415 in the blind hormone therapy arm, and 381 in
the blind placebo arm. Altogether 1823 participants were
recruited at three clinical centers between January 1999
and December 2001. Details of the trial design, randomi-
zation, eligibility criteria, recruitment, and clinical follow-
up of participants are described elsewhere [17]. Trial treat-
ment was stopped by May 2004. The mean follow-up
period for trial participants was 3.6 years. All participants
gave written informed consent. The trial design was
approved by the Tallinn Medical Research Ethics Commit-
tee.
At baseline, the mean age of participants was 58.2 years
(SD 4.0 yrs) and they were on average 8.0 years (SD 4.0)
postmenopausal. Of the recruited women, 15% were cur-
rent smokers, 13% had been treated for hypertension,
1.9% had a history of stenocardia, 0.3% a history of myo-
cardial infarction, and 1.6% a history of diabetes. The
mean body mass index of the trial participants at baseline
was 27.0 kg/m2. At the time of recruitment, 62% were
married and 69% still working, with 33% of participants
having a higher education. The mean parity of the partic-
ipants was 1.8. At the time of joining the trial, 52% of par-
ticipating women were living in the capital, 17% around
it, 21% in a small town, and 10% in the countryside.
There were no significant differences in the background
characteristics of women in different trial arms over time.
Participants in the hormone therapy arms received 0.625
mg of combined estrogens plus 2.5 mg of medroxyproges-
terone acetate daily orally or a matched placebo in the pla-
cebo arm or no treatment in the control arm. The 251
participants who were within three years of their last men-
strual period received 0.625 mg of combined estrogens
plus 5.0 mg of medroxyprogesterone acetate daily orally
or matched placebo or no treatment. A general algorithm
was followed for the management of bleeding depending
on the severity and duration of bleeding.
At the end of the first trial year, 83% of the participants
took over 20% of their assigned trial medication (82% in
the placebo arm), with 57% of participants for the second
year (54% in the placebo arm), 64% of participants for
the third year (54% in the placebo arm), and 63% of par-
ticipants for the whole trial period in the hormone ther-
apy arms using more than 20% of allocated trial treatment
(the mean proportion of adherent women in the placebo
arm for the whole trial period was 59%). Throughout the
trial, some 90% of women in the non-treatment arm did
not start hormone therapy. In the placebo arm, 5% of
women started prescribed hormone therapy. Reasons for
non-adherence have been reported separately [20].
In the non-blind sub-trial, participants and trial staff were
aware of the treatment allocation. In the blind sub-trial,
participants and physicians were blinded as to the compo-
sition of trial treatment. These women were informed
about the composition of their drug within one month of
the closure visit.
Data collection
Prevalence of symptoms was assessed by mailed question-
naires before recruitment, at the end of each trial year, and
at the end of the trial. Quality of life was assessed by cal-
culating EuroQoL (EQ-5D) scores [21] at the end of the
second trial year and also at the time of stopping the trial.
All annual questionnaires included questions about the
prevalence of 17 symptoms in the previous two weeks
(dizzy spells, chronic fatigue, diarrhea or constipation,
irritability, persistent cough, depression, backaches, upset
stomach, headaches, sweating, aches/stiffness in the
joints, shortness of breath, hot flushes, sore throat, trou-
ble sleeping, loss of appetite, water retention) to evaluate
the physical health and psychological status of trial partic-
ipants. The same questions were asked of all participants
before recruitment. All annual questionnaires contained
questions about the presence, number and severity of
bleeding episodes in the previous 12 months. The first
and the final annual questionnaire included questions
about painful intercourse in the previous 12 months.
The second annual and the final questionnaires contained
EQ-5D [21]. EQ-5D is a standardized instrument for
measuring health outcomes. It contains five questions
asking whether the respondent has problems with mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/
depression with three possible responses available (no
problems, moderate problems, severe problems). EQ-5D
is designed for self-completion and provides a single
index score for health status. The lowest possible value for
the EQ-5D index is 0 and the highest possible value is 1.
All participants filled in the recruitment questionnaire.
The response rate was 75% for the first annual survey,
69% for the second annual survey, and 81% for the final
survey mailed at the end of the trial and followed by one
reminder. On average, the final survey was filled in 3.6
years after the recruitment. There were no significant dif-
ferences in the annual response rates between the trial
arms (Table 1).Page 3 of 10
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We used R version 2.5.0 [22] to analyze the data on an
intention-to-treat basis. Numbers of women reporting
vaginal bleeding and number and severity of bleeding epi-
sodes were compared in different trial arms at the end of
the second trial year and at the end of the trial. The pro-
portion of women reporting painful intercourse in differ-
ent trial arms was compared at the end of the first trial year
and at the end of the trial.
For the set of binary indicators on symptom prevalence,
longitudinal data analysis as mixed effects logistic regres-
sion with random subject-specific intercepts, using a
penalized quasi-likelihood method and assuming a first-
order autoregressive dependence structure within subjects
was performed to test if the prevalence of different symp-
toms over time depended on hormone treatment. The
model was adjusted for the presence of these symptoms at
baseline, for time, participant's age and being randomized
to a blind sub-trial or not. In the fitting of models, the
blind and the non-blind hormone therapy arms were
combined as well as the placebo and non-treatment arms
to increase power.
EQ-5D scores were compared in all trial arms at the end of
the second trial year and at the end of the trial. The EQ-5D
score was calculated using the simple formula based
method [23]. Longitudinal data analysis as general linear
mixed effects modeling using restricted maximum likeli-
hood and assuming exponential spatial correlation
between measurements (strength of which depending on
the length of the time interval between measurements)
was used to analyze the effect of age, treatment, time and
blinding on the quality of life.
Results
Symptoms reported most often by all participants at
recruitment were aches or stiffness in joints (56%),
chronic fatigue (53%), sweating (47%), hot flushes
(45%), and backache (40%). There were no baseline dif-
ferences in the prevalence of symptoms in different arms
except for sweating, which was reported more often by
women in the hormone therapy arm (50%) than in the
non-treatment arm (44%) of the non-blind sub-trial
(Table 2).
Longitudinal data analysis showed that throughout the
trial, less women reported hot flushes (OR 0.20; 95% CI:
0.14–0.28), sweating (OR 0.56; 95% CI: 0.44–0.72) and
sleeping problems (OR 0.66; 95% CI: 0.52–0.84) in hor-
mone therapy arms than in non-therapy arms. Prevalence
of hot flushes in different trial arms over time is presented
in Figure 2, prevalence of sweating in Figure 3, and preva-
lence of sleeping problems in Figure 4. The difference
between the trial arms in reporting sleeping problems at
the end of the trial was less evident than at the end of the
second trial year probably due to decrease in adherence
rates. There was no difference between the treatment and
non-treatment arms in reporting depression or any other
symptoms (Table 2).
Longitudinal data analysis showed that hormone therapy
increased the risk of vaginal bleeding substantially (OR
19.65; 95% CI: 12.15–31.79). More women in hormone
therapy arms than in non-therapy arms reported vaginal
bleeding in the previous 12 months both at the end of the
second trial year (58 versus 13) and at the end of the trial
(41 versus 13). The mean number of bleeding episodes
per woman reporting bleeding in the previous 12 months
was also higher in hormone therapy arms both at the end
of the second trial year (3.7 versus 2.1) and at the end of
the trial (3.5 versus 1.2). Bleeding episodes were consid-
ered to have been heavy by more women in hormone
therapy arms than in non-therapy arms at the end of the
second trial year (3 versus 0) and at the end of the trial (4
versus 0).
At the end of the first trial year, less women in hormone
therapy arms (5%) than in non-therapy arms (9%)
reported painful intercourse (OR 0.59; 95%
CI:0.37–0.94), but more women complained of painful
intercourse in hormone therapy arms (6%) than in non-
therapy arms (2%) at the end of the trial (OR 3.12; 95%
CI:1.65–6.25). The proportion of women having had no
intercourse was not significantly different in different trial
arms over time.
According to the EQ-5D questions, there was no differ-
ence between the arms in reporting problems with self-
care, usual activities, pain or discomfort, anxiety or
depression, but problems with mobility were reported
Table 1: Number and proportion of women responding to annual questionnaires by trial arm in the EPHT Trial, 1999–2004
Trial arm Recruitment N (%) 1st year N (%) 2nd year N (%) Final N (%)
Blind HT 415 (100) 315 (75.9) 295 (71.1) 329 (79.3)
Blind placebo 381 (100) 278 (73.0) 254 (66.7) 308 (80.8)
Non-blind HT 503 (100) 371 (73.8) 340 (67.6) 405 (80.5)
Non-treatment 524 (100) 395 (75.4) 374 (71.4) 445 (84.9)
Total 1823 (100) 1359 (74.6) 1263 (69.3) 1487 (81.4)Page 4 of 10
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therapy on symptom reporting
Symptom Non- blind HT (%) Non- treatment (%) Blind HT (%) Placebo (%) OR (95% CI)
Hot flushes
recruitment 43.4 41.1 46.2 48.4 0.20 (0.14–0.28)
2nd year 10.8 22.9 9.1 26.2
final 14.6 23.6 13.1 22.5
Sweating
recruitment 50.0 43.5 46.2 47.2 0.56 (0.44–0.72)
2nd year 23.9 32.4 22.9 32.8
final 26.4 31.8 24.0 31.4
Trouble sleeping
recruitment 31.4 30.3 30.2 34.3 0.66 (0.52–0.84)
2nd year 25.6 31.1 24.9 32.0
final 34.1 36.2 31.3 33.3
Depression
recruitment 27.1 27.2 23.4 21.0 0.81 (0.60–1.08)
2nd year 19.9 21.1 19.2 22.8
final 21.6 23.6 18.9 19.3
Anxiety
recruitment 34.4 36.1 34.6 33.2 0.93 (0.73–1.19)
2nd year 27.1 25.7 28.3 27.8
final 27.3 29.5 25.2 25.2
Backache
recruitment 40.2 40.0 42.1 36.0 1.15 (0.96–1.38)
2nd year 38.7 37.0 35.7 37.3
final 45.4 37.2 39.5 35.6
Stiffness/aches in joints
recruitment 57.5 54.5 56.3 54.2 0.97 (0.82–1.15)
2nd year 50.3 56.4 50.8 57.0
final 57.5 56.5 54.4 56.5
Chronic fatigue
recruitment 55.5 53.9 51.7 49.0 1.11 (0.90–1.35)
2nd year 52.8 51.6 47.5 49.4
final 55.3 49.5 47.7 49.3
Headache
recruitment 39.1 33.3 35.1 38.8 1.08 (0.76–1.54)
2nd year 34.1 30.1 33.3 32.4
final 35.7 30.9 35.3 33.3
Dizzy spells
recruitment 26.6 23.3 21.1 24.7 0.97 (0.74–1.28)
2nd year 18.7 22.3 21.2 19.6
final 19.4 23.0 19.5 16.7
Diarrhoea or constipation
recruitment 26.4 26.6 21.2 21.7 0.99 (0.75–1.30)
2nd year 24.8 20.2 18.6 19.9
final 24.8 24.3 24.3 24.5
Upset stomach
recruitment 12.3 13.3 11.0 7.6 0.92 (0.66–1.29)
2nd year' 11.6 10.1 9.1 10.9
final 9.4 8.3 10.6 8.2
Shortness of breath
recruitment 20.0 14.9 18.5 13.9 0.97 (0.74–1.27)
2nd year 12.2 13.8 9.8 11.3
final 12.9 10.1 10.0 12.1
Sore throat
recruitment 10.4 13.7 10.2 11.4 1.14 (0.85–1.54)
2nd year 11.6 11.7 11.1 7.8
final 12.7 10.4 10.3 10.1
Constant cough
recruitment 6.0 7.9 7.0 6.3 1.11 (0.79–1.56)Page 5 of 10
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(35% of respondents) than by women in the placebo arm
(27% of respondents) at the end of the trial (OR 1.43;
95% CI 1.01–2.05). Despite the differences in reporting
symptoms and problems with mobility, there was no dif-
ference in the distribution of women with different EQ-
5D scores in trial arms at the end of the second trial year
and at the end of the trial. As the distribution of women
with different quality of life scores was strongly skewed,
the results are presented in quartiles (Table 3). For half of
the women in all trial arms, EQ-5D score was 0.90 at the
end of the second trial year and 0.80 at the end of the trial.
Longitudinal data analysis showed that quality of life
decreased with age (estimated difference -0.027 per one
decade, SE = 0.009) and time (estimated difference -0.017
per one trial year, SE = 0.0024), but was not influenced by
treatment or blinding.
Discussion
Our data showed a decrease in reporting vasomotor symp-
toms and sleeping problems in hormone therapy arms,
and an increase in the rates of vaginal bleeding over the
observed period of time. Despite the difference in symp-
Prevalence of sweating in different trial arms in the EPHT T ial over timeFigur  3
Prevalence of sweating in different trial arms in the EPHT 
Trial over time.
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2nd year 6.4 7.2 8.1 6.2
final 9.7 8.6 7.3 5.6
Water retention
recruitment 14.6 16.3 16.6 15.5 1.09 (0.79–1.50)
2nd year 13.4 15.2 14.8 11.8
final 16.2 13.6 16.1 15.1
Loss of appetite
recruitment 3.7 3.4 3.0 3.8 0.91 (0.69–1.20)
2nd year 3.5 2.9 2.0 3.5
final 3.0 3.4 3.3 3.3
Vaginal bleeding
recruitment 3.5 2.3 4.2 2.8 19.65 (12.15–31.79)
1st year 10.3 2.7 9.5 1.2
final 5.9 0.7 4.9 0.7
* Among those whose data available
HT – hormone therapy
OR – combined odds ratio for treatment versus no-treatment arms
CI – confidence interval
Table 2: Proportion of women reporting different symptoms in each arm of the EPHT Trial over time* and the effect of hormone 
therapy on symptom reporting (Continued)
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between different trial arms was observed.
Hormone therapy is not used only around menopause.
Before the publication of the results from the Women's
Health Initiative Trial and the Million Women Study, it
was estimated to be used by a third of postmenopausal
women in Sweden [24], by forty percent in the United
States [25] and by more than forty percent in Finland [26]
for up to fifteen years after menopause. After publication
of the findings from these studies the use of hormone
therapy declined [27-31], but still hormone therapy is
used by tens of millions of women all over the world.
Women interested in participating in the trial were
younger and more frequently reported depression and
trouble sleeping than women not interested in participa-
tion. There was no difference in other socioeconomic
characteristics and the reporting of other symptoms
inquired about in the recruitment questionnaire [32].
We assume the higher proportion of women reporting
sweats in the non-blind hormone therapy arm at recruit-
ment to be a chance finding as treatment allocation was
not known before recruitment. No significant difference
in the numbers of women reporting sweats at baseline was
observed between hormone therapy and non-treatment
arms after combining data from both sub-trials. There-
fore, the difference was not taken into account in the sta-
tistical analysis.
The proportion of women reporting problems in different
trial arms at recruitment was higher than during the trial,
probably because not all women with symptoms at
recruitment responded to annual questionnaires. As the
response rates to the annual questionnaires varied and the
final questionnaire was completed at a different time, lon-
gitudinal data analysis was used to estimate the effect of
hormone therapy on the prevalence of symptoms and
quality of life over time.
No data for EQ-5D was collected at baseline. We assume
that the EQ-5D scores at baseline were similar in all trial
arms. Even though EQ-5D asks about mobility, self-care,
usual activities, pain and anxiety or depression and is said
to be one of the bluntest health-status instruments availa-
ble [33], EQ-5D has been found to be suitable for meas-
uring health-related quality of life among gynecological
patients in all age groups [34]. It is more likely to elicit a
response than complicated measurement tools [35].
The beneficial effect of hormone therapy on vasomotor
symptoms is well established [4-7] as well as bleeding as
Table 3: Distribution of women with different quality of life scores in each arm of the EPHT Trial over time
EQ-5D score
Survey year/trial arm Minimum 1st quartile Median 3rd quartile Maximum
2nd year
Non-blind HT 0.30 0.80 0.90 1.00 1.00
Non-treatment 0.40 0.70 0.90 1.00 1.00
Blind HT 0.30 0.80 0.90 1.00 1.00
Blind placebo 0.30 0.80 0.90 1.00 1.00
Final
Non-blind HT 0.40 0.70 0.80 0.90 1.00
Non-treatment 0.30 0.70 0.80 0.90 1.00
Blind HT 0.30 0.70 0.80 0.90 1.00
Blind placebo 0.10 0.70 0.80 0.90 1.00
EQ-5D – quality of life according to EQ-5D score
HT – hormone therapy
Prevalence of sleeping problems in different trial arms in the EPHT Trial ver timeFigur  4
Prevalence of sleeping problems in different trial arms in the 
EPHT Trial over time.
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disturbance has earlier been reported over a shorter period
of time [15,36]. Although transition to menopause has
been found to be associated with depressed mood [37],
we found no difference in the proportion of women
reporting depression in different trial arms.
Low adherence rates in the treatment arms may have
diluted the effect of hormone therapy. The inconsistent
effect of hormone therapy on painful intercourse during
the EPHT Trial could be explained by lower adherence
rates at the end of the trial in comparison with the adher-
ence rates in hormone therapy arms at the end of the first
trial year. Women were not persuaded to continue trial
treatment, and the fall in adherence rates was the same as
in real life circumstances [38].
Overall quality of life scores decreased with increasing
age. The problems with mobility reported more often by
women in hormone therapy arms in the EQ-5D question-
naire at the end of the trial may be a chance finding. The
results are presented separately for both the blind and the
non-blind sub-trial. Blinding had no effect on symptom
reporting or quality of life over time.
In the WHI Trial, moderate to severe hot flushes were
reported by 24% of participants aged 50–54 years and
15% for women aged 55–59 years at baseline, and night
sweats by 21% and 14% accordingly [14]. In the HERS
Trial, hot flushes were reported by 16% of participants at
baseline [13]. In the EPHT Trial, the proportion of women
with vasomotor symptoms was higher (Table 2).
In the WHI Trial, changes in menopausal symptoms were
analyzed at the end of the first trial year [14], and quality
of life was measured at baseline, at year one, and in a sub-
group of women in year three [15]. In the HERS Trial,
quality of life and depressive symptoms were measured at
a three-year follow-up [13]. In the EPHT Trial, data on
symptom reporting was collected annually, data on qual-
ity of life at year two and at the end of the trial, the mean
follow-up period being 3.6 years.
In the WHI Trial, quality of life was assessed with the use
of the RAND-36 Health Survey, and in addition data
about depressive symptoms, sleep disturbance, sexual and
cognitive functioning, and menopausal symptoms were
collected [15]. In the HERS Trial, physical activity was
measured by the Duke Activity Status Index, energy and
mental health by RAND scales, and depressive symptoms
on the Burnam scale [13].
According to the WHI Trial data, combined hormone
therapy improved vasomotor symptoms, vaginal or geni-
tal dryness, and all pain symptoms, but increased the rates
of breast tenderness during the first year of use and vagi-
nal bleeding persistently [14]. No clinically meaningful
effect on health-related quality of life was detected [15].
The HERS trial data suggested that quality of life generally
declined during the follow-up and hormone therapy had
negative effects on physical function, but it improved
depressive symptoms and quality of life for women with
menopausal symptoms [13].
The follow-up period for symptom reporting and quality
of life in the EPHT Trial was longer than in the WHI and
HERS trials, while the regimen used was the same. The dif-
ference in outcomes can be explained by the difference in
the participants' health indicators and age, by the differ-
ence in measurement tools, and by cross-cultural differ-
ences [39].
Conclusion
Data from the EPHT Trial show that postmenopausal hor-
mone therapy decreased hot flushes, sweating, and sleep
disorders, but increased episodes of vaginal bleeding. No
effect on quality of life was observed. Physicians prescrib-
ing hormone therapy for postmenopausal women should
take into account the complex of the effects of hormone
therapy.
Health-related quality of life may also be influenced by
cultural and socio-economic factors [40], therefore all
tools that measure quality of life are highly influenced by
personality and social circumstances [41]. Which factors
influence the quality of life in the ageing population in
different cultural contexts deserves additional research,
and measurement tools for quality of life could be further
developed. The underlying mechanisms for subjective
symptoms among postmenopausal women require future
clinical research.
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